ML323,
1572414-83-5,
ML-323,
ML 323,
N-(4-(1H-1,2,3-triazol-1-yl)benzyl)-2-(2-isopropylphenyl)-5-methylpyrimidin-4-amine,
CHEMBL3182437,
5-methyl-2-(2-propan-2-ylphenyl)-N-[[4-(triazol-1-yl)phenyl]methyl]pyrimidin-4-amine,
C23H24N6,
GTPL7898,
SCHEMBL15847799,
AOB2313,
EX-A392,
HMS3653L13,
BCP09653,
KS-00000T6E,
2555AH,
BDBM50069762,
MFCD28099817,
s7529,
ZINC98023188,
AKOS026750196,
CS-2274,
SB19053,
NCGC00262306-01,
NCGC00262306-02,
NCGC00262306-25,
AK175629,
AS-16712,
BC600443,
DA-43946,
HY-17543,
QC-11769,
SC-91485,
FT-0700457,
SW219291-1,
A14030,
J-690211,
4-Pyrimidinamine, 5-methyl-2-[2-(1-methylethyl)phe,
2-(2-ISOPROPYLPHENYL)-5-METHYL-N-{[4-(1,2,3-TRIAZOL-1-YL)PHENYL]METHYL}PYRIMIDIN-4-AMINE,
5-Methyl-2-[2-(1-methylethyl)phenyl]-N-[[4-(1H-1,2,3-triazol-1-yl)phenyl]methyl]-4-pyrimidinamine,
N-{3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl}-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-4-biphenylcarboxamide,
D0M5FO,
ML323, 99%, an USP1-UAF1 inhibitor - 25MG 25mg,
N-(4-(1H-1,2,3-triazol-1-yl)benzyl)-2-(2-isopropylphenyl)-5-methylpyrimidin -4-amine,